Kolmar BNH gets approval for health functional food ingredient in US

This company develops its own balsam apple extract, used for blood sugar management

Kolmar BNH gets approval for health functional food ingredient in US
Yoo-Rim Kim 1
2023-04-20 16:49:13 youforest@hankyung.com
Food & Beverage

Kolmar BNH Co. has received approval from the US Food and Drug Administration (FDA) for a domestically developed health functional food ingredient.

Kolmar BNH announced on Thursday that its individually recognized, balsam apple alcohol extract powder (Sugar Katcher S52™) has been approved by the FDA as a new dietary ingredient (NDI).

An NDI is a system in which the FDA authorizes the use of newly developed dietary ingredients. It must undergo evaluation processes such as ingredient, production, toxicity, and human application tests.

The newly listed ingredient was developed by Kolmar BNH's Food Science Lab, which studied and developed the unripe bitter melon alcohol extract powder for six years. Kolmar BNH has proven that unripe dried bitter melon, which has not yet formed seeds, activates substances that promote blood sugar metabolism and suppress body fat accumulation.

The company plans to develop products that improve the functionality and intake of unripe dried bitter melon extract powder based on the FDA's NDI approval and expand its presence in both domestic and international markets.

Write to Yoo-Rim Kim at youforest@hankyung.com

S.Korea's Celltrion Healthcare launches Vegzelma in US

S.Korea's Celltrion Healthcare launches Vegzelma in US

South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorectal and breast cancer sold under the name Avastin.The company has prepared for the launch since September last year, when it received approval to se

Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, has received "therapeutic use approval" for patients with advanced liver cancer. The approval was granted by the Korean Ministry of Food and D

S.Korea's FutureChem gets approval for phase 3 clinical trials in China

S.Korea's FutureChem gets approval for phase 3 clinical trials in China

South Korean radiopharmaceutical development company FutureChem Co. announced on Thursday that China's National Medical Products Administration (NMPA) has granted approval for a phase 3 clinical trial of its radiopharmaceutical drug FC303 for diagnosing prostate cancer in China.Compared to con

Daewoong wins approval for GERD treatment Fexuclu in Chile

Daewoong wins approval for GERD treatment Fexuclu in Chile

Daewoong's Fexuclue South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National Medicines Agency Department (ANAMED) within the Public Health Institute for its gastroesophageal reflux disease drug (GERD) Fex

GC Biopharma gets WHO pre-qualification approval for chickenpox vaccine

GC Biopharma gets WHO pre-qualification approval for chickenpox vaccine

South Korea's GC Biopharma Co. is set to regain the No. 1 spot in global production of chickenpox vaccines after earning qualification to enter the World Health Organization (WHO) procurement market with Barycela following its export hit Suduvax. This breakthrough is expected to heat up global

(* comment hide *}